RBM Nets Biomarker Milestone in Ongoing CNS PGx Collaboration with Roche
June 01, 2011
RBM Nets Biomarker Milestone in Ongoing CNS PGx Collaboration with Roche
The company used its DiscoveryMAP quantitative immunoassay platform to identify a promising multi-protein biomarker pattern using blood samples provided by Roche from a late-stage drug trial.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Myriad Highlights RBM Pharma Work, Reports $2M in Q4 Revenues from Companion Diagnostics
August 12, 2011 / ProteoMonitor - RBM Achieves Milestone in Companion Diagnostic Project with Roche
May 27, 2011 / ProteoMonitor - Myriad to Enter Proteomics Market with $80M Purchase of Rules-Based Medicine
April 29, 2011 / ProteoMonitor - Roche Inks Deal with RBM/Psynova to Develop Diagnostics for 'Differentiating' Schizophrenia Therapies
December 9, 2009 / Pharmacogenomics Reporter - MDx/CDx Focus: EMA Okays Perjeta; Published Study on Prolaris; HER2 Tests for Kadcyla Clear FDA
March 6, 2013 / Pharmacogenomics Reporter